Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 340

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 340
---
arrant will also be adjusted so that the aggregate exercise price shall be the same immediately before and immediately after any such adjustment. We had the right, conditional upon the share price of CERO stock to be trading above $ 100.00per share, to require the holders of Preferred Warrants to exercise such Preferred Warrants into up to an aggregate number of shares of Preferred Stock equal to the holder’s pro rata amount of 2,500shares of Preferred Stock. In connection with the Series C PIPE Financing, we agreed with certain holders of the Preferred Warrants not to exercise such right to require such exercise by the holders thereof in consideration for their investment in the Series C PIPE Financing. The Preferred Warrants prohibited us from entering into specified fundamental transactions unless the Successor assumes all of our obligations under the Preferred Warrants under a written agreement before the transaction is completed. Upon specified corporate events, a holder of the Preferred Warrants thereafter had the right to receive upon an exercise such shares, securities, cash, assets or any other property whatsoever which the holder would have been entitled to receive upon the happening of the applicable corporate event had the Preferred Warrant been exercised immediately prior to the applicable corporate event. During the three months ended March 31, 2025, 625Series A Preferred Warrants were exercised into 625shares of Series A Preferred Stock for gross proceeds of $ 500,000. During the three months ended March 31, 2024, no Series A Preferred Warrants were exercised into shares of Series A Preferred Stock. The Company’s Preferred Warrants were exercisable into Series A Preferred Stock, which had no cash redemption features that required liability treatment. The Company recorded the Preferred Warrants as equity. February 2025 Pre-funded Warrants and February 2025 Common Warrants On February 5, 2025, in connection with the February 2025 Offering (See Note 8), the Company sold (i) 300,000shares of Common Stock, (ii) Pre-Funded Warrants to purchase up to 2,251,020shares of Common Stock, and (iii) Common Warrants to purchase up to 2,551,020shares of common stock, at a combined public offering price of $ 1.96per share and Warrant. During the three months ended March 31, 2025, 1,824,280shares of its common stock were issued following the exercise of certain Pre-Funded Warrants. As of March 31, 2025, The